Notably, Flow Neuroscience has announced pivotal trial results that are particularly promising. Their FDA-approved clinical trial found that their tDCS headset was twice as effective as commonly prescribed antidepressants. In this trial, 56% of participants using the Flow tDCS headset were completely relieved of depressive symptoms within 10 weeks.
Moreover, the largest clinical trial to date for a portable tDCS device for depression treatment is underway, with 270 participants across two research centers in the USA and the UK. This study is notable for its scope and for the high level of autonomy it provides to participants, who use the device and participate in the study from home. Early results have been positive, with many patients experiencing significant reductions in depressive symptoms.
These findings point to tDCS as a potentially transformative non-pharmacological treatment for depression, emphasizing its efficacy and safety when administered properly. The ease of use at home and minimal side effects make it an appealing option for many individuals seeking alternatives to traditional medications. For more detailed insights, you can check out the full reports on NeuroNews International.
Interested in trying tDCS yourself at home? Read our post on the best tDCS devices on the market.
